<DOC>
	<DOCNO>NCT01380691</DOCNO>
	<brief_summary>This study evaluate pharmacodynamic pharmacokinetic interaction LY2216684 Alcohol Healthy Subjects . This study run approximately 34 day .</brief_summary>
	<brief_title>A Study LY2216684 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination Male subject : Agree use reliable method birth control study 1 month follow last dose study drug . Female subject : Are woman childbearing potential test negative pregnancy time enrollment , use reliable method birth control 6 week prior administration study drug , agree use reliable method birth control study 1 month follow last dose study drug ( hormonal method contraception , include oral implantable contraceptive , allow study ) ; Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause ( least 1 year without menses 6 month without menses follicle stimulate hormone [ FSH ] &gt; 40 mIU/mL ) . Male female subject : Examples reliable method birth control include : Doublebarrier method ( eg , condom spermicide ) alone combination vasectomy , vasectomized partner , abstinence . Have body weight &gt; 50 kg Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly institutional review board ( IRB ) govern site Have normal blood pressure pulse rate ( sit position ) determine investigator Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product study drug use study ; concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2216684 , related compound component formulation Are person previously receive investigational product study complete withdrawn study study investigate LY2216684 within 6 month prior Screening Have abnormality 12lead Electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study . Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history show evidence significant active neuropsychiatric disease history suicide attempt ideation Regularly use know drug abuse and/or show positive finding urinary drug screen Subjects past history alcohol dependence/abuse Show evidence human immunodeficiency virus ( HIV ) infection and/or positive HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Intend use overthecounter prescription medication within 14 day prior dose study unless deem acceptable investigator Sponsor 's medical monitor , except influenza vaccination Have donate blood 500 mL within last month Have average weekly alcohol intake exceed 14 unit per week , unwilling stop alcohol consumption 48 hour prior study period resident Clinical Research Unit ( CRU ) ( except require per protocol ) ; ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Consume 5 cup coffee ( beverage comparable caffeine content ) per day , habitual basis , subject unwilling adhere study caffeine restriction Have consume grapefruit grapefruitcontaining product 7 day prior enrollment unwilling abstain study Have document suspected history glaucoma Subjects know suspect alcohol dehydrogenase deficiency Subjects drink alcohol and/or willing drink 4 unit alcohol 15minute period Subjects determine unsuitable investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>